Search results for "high risk patient"

showing 10 items of 14 documents

High-Risk Patients with Differentiated Thyroid Cancer T4 Primary Tumors Achieve Remnant Ablation Equally Well Using rhTSH or Thyroid Hormone Withdraw…

2013

Few data exist on using thyrotropin alfa (recombinant human thyroid-stimulating hormone [rhTSH]) with radioiodine for thyroid remnant ablation of patients who have T4 primary tumors (invasion beyond the thyroid capsule).A retrospective chart review protocol at nine centers in Europe was set up with special waiver of need for informed consent, along with a careful procedure to avoid selection bias when enrolling patients into the database. Data on 144 eligible patients with T4 tumors were collected (T4, N0-1, M0-1; mean age 49.7 years; 65% female; 88% papillary cancer). All had received (131)I remnant ablation following TSH stimulation with rhTSH or thyroid hormone withdrawal (THW) since Jan…

AdultMalemedicine.medical_specialtyNeoplasm ResidualEndocrinology Diabetes and Metabolismmedicine.medical_treatmentUrologyRemnant ablationIodine RadioisotopesYoung AdultEndocrinologyClinical endpointmedicineHumansThyroid NeoplasmsThyrotropin AlfaThyroid cancerAgedRetrospective StudiesAged 80 and overHigh risk patientsbusiness.industryThyroidCancerMiddle Agedmedicine.diseaseAblationCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureThyroidectomyFemalebusinessHormoneThyroid
researchProduct

Anästhesiemanagement bei Hochrisikopatienten - „Der nicht narkosefähige Patient”: Versuch einer Begriffsbestimmung

1997

Anesthesiology and Pain MedicineHigh risk patientsbusiness.industryAnesthesiaEmergency MedicineMedicineGeneral MedicineRisk factorCritical Care and Intensive Care MedicineComplicationbusinessAINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie
researchProduct

Patterns of transmitted HIV drug resistance in Europe vary by risk group

2014

BACKGROUND: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. METHODS: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. RESULTS: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM…

MaleEpidemiologygenotypeHuman immunodeficiency virus 1HIV InfectionsRNA directed DNA polymerase inhibitorhigh risk patientLogistic regressionSettore MED/42 - Igiene Generale E ApplicataMen who have sex with men0302 clinical medicineImmunodeficiency Virusesmiddle agedstatistics and numerical data10. No inequalitySubstance Abuse Intravenous0303 health sciencesadulttransmissionvirus diseasesvirus transmissionhighly active antiretroviral therapyHIV immunopathogenesis3. Good healthMedical MicrobiologyViral Pathogenshigh risk behaviorMedicineScience & Technology - Other TopicsPOPULATIONShealth programanti human immunodeficiency virus agentUSERSmedicine.medical_specialtyScienceSexual BehaviorImmunologySexually Transmitted Diseasesintravenous drug abuse-Microbiology03 medical and health sciencesAntibiotic resistanceSDG 3 - Good Health and Well-beingHuman immunodeficiency virus infectionproteinase inhibitorHumansProtease InhibitorshumanHeterosexualityMicrobial PathogensseroconversionMedicine and health sciencesScience & TechnologyGenitourinary InfectionsMUTATIONSVirologymajor clinical studyLogistic Modelstransmitted drug resistance mutationHeterosexualityHIV-1Viral Diseases:Medical sciences: 700::Basic medical dental and veterinary sciences: 710::Medical immunology: 716 [VDP]drug responsemen who have sex with menDrug resistanceClinical immunologygeographyAPPEARANCEmale homosexualityMedizinische Fakultätimmune system diseasesEpidemiologyINFECTIONMedicine and Health Sciencessubstance abuse030212 general & internal medicineriskMultidisciplinaryACTIVE ANTIRETROVIRAL THERAPYTransmission (medicine)virus mutationQRarticleObstetrics and GynecologyHIV diagnosis and managementMiddle AgedvirologyMultidisciplinary SciencesEuropeInfectious Diseasesfemale:Medisinske fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Medisinsk immunologi: 716 [VDP]Reverse Transcriptase InhibitorsHIV clinical manifestationsFemaleepidemiologyblood samplingHIV drug resistanceResearch ArticleAdultRiskrisk-groupAnti-HIV AgentsUrologyprevalenceInfectious Disease Epidemiologysexual behaviorRisk-Takingmaleantiviral resistanceInternal medicineDrug Resistance Viralmedicinecontrolled studyddc:610Homosexuality Male030304 developmental biologydrug resistanceBiology and life sciencesbusiness.industrystatistical modelHIVCD4 lymphocyte countheterosexualitynonnucleoside reverse transcriptase inhibitorHuman immunodeficiency virus 1 infectionDiagnostic medicineINDIVIDUALSdrug effectsWomen's Healthbusinesstrend study
researchProduct

Mid-term Results of Chimney and Periscope Grafts in Supra-aortic Branches in High Risk Patients

2017

Purpose Report mid-term outcomes of thoracic endovascular aneurysm repair (TEVAR) with chimney and periscope grafts (CPG) in supra-aortic branches (SAB). Methods Retrospective analysis, from October 2009 to May 2014, of patients with aneurysms requiring TEVAR with zone 0/1/2 proximal landing in association with at least one CPG in the SAB. All patients were considered at high risk for conventional surgery. Peri-operative mortality and morbidity, retrograde type A dissection, maximum aortic transverse diameter (TD) and its post-operative evolution, endoleak, survival, freedom from cardiovascular re-interventions, and CPG freedom from occlusion during the follow-up were analysed. Results Fort…

MaleTime FactorsEndoleakComputed Tomography Angiographymedicine.medical_treatmentMid term resultsKaplan-Meier Estimate030204 cardiovascular system & hematologySettore MED/22 - Chirurgia VascolareEndovascular aneurysm repairAortic aneurysmPostoperative Complications0302 clinical medicineRisk FactorsOcclusionMedicine030212 general & internal medicineAortic arch aneurysm; Chimney graft/technique; Endoleak; Endovascular aneurysm repair; Parallel graft; Periscope graft; Surgery; Cardiology and Cardiovascular MedicineAged 80 and overeducation.field_of_studyHigh risk patients10042 Clinic for Diagnostic and Interventional RadiologyEndovascular ProceduresMiddle Aged2746 SurgeryTreatment Outcomecardiovascular systemFemaleRadiologyCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyPopulation610 Medicine & healthProsthesis DesignAortographyRisk AssessmentDisease-Free Survival2705 Cardiology and Cardiovascular MedicineBlood Vessel Prosthesis ImplantationEndovascular aneurysm repair03 medical and health sciencesAneurysmmedicine.arteryHumanseducationAgedRetrospective StudiesAortaAortic Aneurysm ThoracicParallel graftAortic arch aneurysmbusiness.industryPatient SelectionChimney graft/techniquemedicine.diseaseBlood Vessel Prosthesis10020 Clinic for Cardiac SurgerySurgeryPeriscope graftSurgerybusinessEuropean Journal of Vascular and Endovascular Surgery
researchProduct

Antifungal prophylaxis for invasive mycoses in high risk patients.

2006

New broader spectrum antifungal agents with favorable safety profiles have been available for the last 15 years making prophylaxis feasible. The purpose of this article is to review recent studies in patient populations at high risk for invasive fungal infections.Itraconazole, lipid formulations of amphotericin B, posaconazole, caspofungin and micafungin have been utilized for prophylaxis in different immunocompromised host settings. Itraconazole and caspofungin remain an option especially in patients with hematological diseases. Low dose liposomal amphotericin B shows a lower morbidity rate in patients treated for acute myeloid leukemia. Posaconazole demonstrated survival benefits in this …

Microbiology (medical)Antifungalmedicine.medical_specialtyClinical Trials as TopicHigh risk patientsAntifungal Agentsbusiness.industrymedicine.drug_classImmunocompromised HostInfectious DiseasesInvasive MycosesMycosesMedicineHumansIn patientbusinessIntensive care medicineCurrent opinion in infectious diseases
researchProduct

Meta-analysis on the application of the ERAS protocol in high-risk patients in colorectal surgery

2016

OncologyProtocol (science)medicine.medical_specialtyNutrition and DieteticsHigh risk patientsbusiness.industryEndocrinology Diabetes and MetabolismInternal medicineMeta-analysisMedicinebusinessColorectal surgeryClinical Nutrition ESPEN
researchProduct

HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma

2015

Abstract: The diagnosis and treatment of hepatocellular carcinoma (HCC) underwent a huge advancement in the last years. Recently, microRNAs (miRNAs) have been also studied to provide a new tool for early diagnosis of high risk patients, for prognostic classification to identify those patients who benefit cancer treatment and for predictive definition to select the right targeted drug. In this review we revised all the available data obtained to explore the role of miRNAs in HCC. This analysis led to identification of miRNAs which could gain a diagnostic, prognostic or predictive role. The results of studies on miRNAs involved in HCC are initial and far from providing scientific evidences to…

Serum0301 basic medicineCarcinoma HepatocellularHepatocellular carcinomaPrognosimedicine.medical_treatmentBioinformaticsTargeted therapyTargeted therapy03 medical and health sciences0302 clinical medicinePrognostic classificationBiomarkers TumormedicineHumansProspective cohort studyHigh risk patientsbusiness.industryLiver NeoplasmsMicroRNAHematologyPrognosismedicine.diseaseCancer treatmentClinical PracticeMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisHepatocellular carcinomaHuman medicineDiagnosis; Hepatocellular carcinoma; MicroRNA; Prognosis; Serum; Targeted therapy; Hematology; Oncology; Geriatrics and GerontologyGeriatrics and GerontologybusinessDiagnosiCritical Reviews in Oncology/Hematology
researchProduct

Which patients at risk of cardiovascular disease might benefit the most from inclisiran? – The expert opinion of the Polish experts. The compromise b…

2022

It is the statement of the Polish Experts on the group of patients that might benefit the most from inclisiran. We indicated the fastest way to have inclisiran available for the polish patients, with the necessary changes of the existing drug program for PCSK9 inhibitors (B-101), explaining why it is the optimal way, and why, taking into account available EBM data (the ORION program), inclisiran should be added to this program. We also present some perspective on the future necessary changes in the availability of the innovative therapies such us PCSK9 targeted therapy, what, taking into account the effectiveness of LDL-C goal achievement in Poland for very high CVD risk patients (only 17%)…

drug programlipid lowering therapyhigh risk patientsGeneral MedicinePolandinclisiranreimbursementArchives of Medical Science
researchProduct

Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival

2022

Abstract Background An enhanced surveillance schedule has been proposed for cirrhotics with viral etiology, who are considered at extremely high-risk of hepatocellular carcinoma (HCC). Aims We compared the 3- and 6-months surveillance interval, evaluating cancer stage at diagnosis and patient survival. Methods Data of 777 HBV and HCV cirrhotic patients with HCC diagnosed under a 3-months (n = 109, 3MS group) or a 6-months (n = 668, 6MS group) surveillance were retrieved from the Italian Liver Cancer database. Survival in the 3MS group was considered as observed and adjusted for lead-time bias, and survival analysis was repeated after a propensity score matching. Results The 3-months surveil…

medicine.medical_specialtyCarcinoma HepatocellularSurvivalHepatocellular carcinomaCancer stageCancer stage; Hepatocellular carcinoma; Surveillance interval; SurvivalInternal medicinemedicineHumansPropensity ScoreSurveillance intervalSurvival analysisHigh risk patientsHepatologybusiness.industryCancer stageLiver NeoplasmsSettore MED/09 - MEDICINA INTERNAGastroenterologyPatient survivalmedicine.diseaseSurvival AnalysisHepatocellular carcinomaPropensity score matchingSurvival AnalysiLiver cancerbusinessMedian survivalHuman
researchProduct

Carotid artery stenting outcomes in high-risk patients receiving best medical therapy: results from a single high-volume interventional cardiology pr…

2016

Kontext: Implantace stentů do karotických tepen (carotid artery stenting, CAS) se v soucasnosti ve velkem měřitku použiva v lecbě stenozy karotických tepen. Klinicke studie z posledni doby prokazaly nizkou incidenci přihod po CAS. Tato studie hodnoti 30denni a rocni výsledky pacientů lecených pro CAS intenzivni farmakoterapii na pracovisti provadějicim vysoke pocty perkutannich koronarnich intervenci rocně.Metoda: V obdobi od ledna 2011 do prosince 2013 byla CAS provedena celkem u 184 pacientů. Mimo protidestickove lecby byla provaděna i intenzivni antihypertenzni lecba spolu s vysoce intenzivni terapii statiny a lecbou zaměřenou na normalizaci srdecni frekvence. Pacienti byli stratifikovan…

medicine.medical_specialtyHigh risk patientsInterventional cardiologybusiness.industryCarotid arteries030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineCarotid artery diseaseMedicineCardiology and Cardiovascular MedicinebusinessNuclear medicineMedical therapy030217 neurology & neurosurgeryCor et Vasa
researchProduct